MOUNTAIN VIEW, Calif. (April 17, 2007) – Conceptus, Inc. (Nasdaq: CPTS), developer of the Essure® procedure, the first and only non-incisional permanent birth control method available, today announced that the Company will release 2007 first quarter financial results on Monday, April 30, 2007 after the close of market. Management will host an investment community conference call beginning at 4:30 p.m. Eastern Time on April 30 to discuss the results and to answer questions.

To participate in the live call by telephone, please dial (888) 803-8296 from the U.S., or for international callers, please dial (706) 634-1250. Individuals interested in listening to the live conference call via the Internet may do so by logging on to the Company’s website, www.conceptus.com. A replay will be available on the website for 14 days.

A telephone replay will be available from 6:30 p.m. Eastern Time April 30, 2007 through 11:59 p.m. Eastern Time on May 2, 2007 by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 6165731.

About the Essure Procedure
The Essure procedure, approved by the FDA in 2002, deploys a soft micro-insert into the fallopian tube through the cervix using a minimally invasive transcervical tubal access catheter. Once in place, the device is designed to elicit tissue growth in and around the micro-insert to form an occlusion or blockage in the fallopian tube. An Essure procedure does not require cutting or penetrating the abdomen and can be performed in a less costly procedure setting without general anesthesia. A woman is able to return home about 45 minutes after the procedure is completed. There is a three-month waiting period after the procedure during which women must use another form of birth control. The Essure procedure is 99.80% effective (based on four years of follow-up data). The Essure procedure has been demonstrated in a small portion of the women undergoing clinical studies to be 99.74% effective (based on 5 years of follow-up data). Five-year follow-up of all patients in clinical trials is ongoing.

About Conceptus
Conceptus, Inc. manufactures and markets the Essure Permanent Birth Control system, an innovative medical device and procedure designed to provide a non-incisional alternative to tubal ligation, which is currently the leading form of birth control worldwide. The availability of the Essure procedure in the U.S. is expected to open up a market currently occupied by incisional tubal ligation and vasectomy, which combined account for more than 1 million procedures annually.

Additional information about the Essure procedure is available at www.essure.com or by calling the Essure Information Center at 1-877-ESSURE1. Additional information about Conceptus is available atwww.conceptus.com or by calling 1-877-ESSURE2.